Trecondi
treosulfan
Table of contents
Overview
Trecondi is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells.
Trecondi is used together with another medicine called fludarabine in adults and children from 1 month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant.
The active substance in Trecondi is treosulfan.
Haematopoietic stem cell transplantation is rare, and Trecondi was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 23 February 2004.
-
List item
Trecondi : EPAR - Medicine overview (PDF/78.67 KB)
First published: 22/07/2019
EMA/887197/2018 -
-
List item
Trecondi : EPAR - Risk-management-plan summary (PDF/162.91 KB)
First published: 22/07/2019
Authorisation details
Product details | |
---|---|
Name |
Trecondi
|
Agency product number |
EMEA/H/C/004751
|
Active substance |
Treosulfan
|
International non-proprietary name (INN) or common name |
treosulfan
|
Therapeutic area (MeSH) |
Hematopoietic Stem Cell Transplantation
|
Anatomical therapeutic chemical (ATC) code |
L01AB02
|
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
medac Gesellschaft für klinische Spezialpräparate mbH
|
Revision |
2
|
Date of issue of marketing authorisation valid throughout the European Union |
20/06/2019
|
Contact address |
Product information
23/07/2020 Trecondi - EMEA/H/C/004751 - II/0003/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases.